Ali Reza Sobhani1, Hossein Farshidi2, Fariba Azarkish3, Mahdiya Eslami2, Ebrahim Eftekhar4, Mansoor Keshavarz5, Nepton Soltani6. 1. Clinical Pathology Department, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 2. Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 3. Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 4. Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 5. Physiology Department, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 6. Physiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
PURPOSE: Given the beneficial effect of MgSO4 on the cardiovascular system, this study was designed to investigate the effect of MgSO4 administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels. PATIENTS AND METHODS: In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55-69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO4 (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO4 supplement capsule containing 300 mg MgSO4 for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months. RESULTS: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups. CONCLUSION: The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO4for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.
PURPOSE: Given the beneficial effect of MgSO4 on the cardiovascular system, this study was designed to investigate the effect of MgSO4 administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels. PATIENTS AND METHODS: In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55-69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO4 (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO4 supplement capsule containing 300 mg MgSO4 for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months. RESULTS: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups. CONCLUSION: The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO4for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.
Authors: Thorsten Reffelmann; Till Ittermann; Marcus Dörr; Henry Völzke; Markus Reinthaler; Astrid Petersmann; Stephan B Felix Journal: Atherosclerosis Date: 2011-06-12 Impact factor: 5.162
Authors: Nicolas Rodondi; Wendy P J den Elzen; Douglas C Bauer; Anne R Cappola; Salman Razvi; John P Walsh; Bjørn O Asvold; Giorgio Iervasi; Misa Imaizumi; Tinh-Hai Collet; Alexandra Bremner; Patrick Maisonneuve; José A Sgarbi; Kay-Tee Khaw; Mark P J Vanderpump; Anne B Newman; Jacques Cornuz; Jayne A Franklyn; Rudi G J Westendorp; Eric Vittinghoff; Jacobijn Gussekloo Journal: JAMA Date: 2010-09-22 Impact factor: 56.272
Authors: Xin Fang; Hedong Han; Mei Li; Chun Liang; Zhongjie Fan; Jan Aaseth; Jia He; Scott Montgomery; Yang Cao Journal: Nutrients Date: 2016-11-19 Impact factor: 5.717
Authors: Doaaa Shahbah; Tamer Hassan; Saeed Morsy; Hosam El Saadany; Manar Fathy; Ashgan Al-Ghobashy; Nahla Elsamad; Ahmed Emam; Ahmed Elhewala; Boshra Ibrahim; Sherief El Gebaly; Hany El Sayed; Hanan Ahmed Journal: Medicine (Baltimore) Date: 2017-03 Impact factor: 1.889
Authors: Brenda C T Kieboom; Maartje N Niemeijer; Maarten J G Leening; Marten E van den Berg; Oscar H Franco; Jaap W Deckers; Albert Hofman; Robert Zietse; Bruno H Stricker; Ewout J Hoorn Journal: J Am Heart Assoc Date: 2016-01-22 Impact factor: 5.501